Regeneron
REGN BiotechBiotechnology leader known for Eylea (ophthalmology) and Dupixent (immunology, co-developed with Sanofi). Strong antibody discovery platform.
FDA Novel Drug Designations
(2017-2023)See 5 novel approvals →
Regeneron at a Glance
- Growing R&D activity with 71 trials in last 2 years
- Fast trial execution (19 months median completion)
Regeneron's Key Drugs
Regeneron's core commercial portfolio centers on DUPIXENT, EYLEA, PRALUENT, spanning Oncology and Cardiovascular — its most strategically important drugs approved in the last 15 years.
Atopic Dermatitis
Neovascular (Wet) Age-Related Macular Degeneration (AMD)
Major adverse cardiovascular events risk reduction in adults
Metastatic cutaneous squamous cell carcinoma
Homozygous Familial Hypercholesterolemia
Regeneron News
All Regeneron news →- Nov 12, 2026 TrialsPOTS Phase 2 Trial Shows Baloncibart, a First-in-Class NPR1 Blocking Antibody, Reduced Orthostatic Heart Rate and Improved Orthostatic Symptoms ↗
- Nov 8, 2026 TrialsCIDEBsiRNA Normalizes Liver Fat and Improves Liver Injury Markers in MASLD Patients, as Highlighted at AASLD ↗
- Oct 30, 2026 EarningsRegeneron Reports Third Quarter 2026 Financial and Operating Results ↗
- Oct 26, 2026 DealsRegeneron Extends Agreement with BARDA to Provide Additional Supply of Ebola Treatment Inmazeb® for U.S. Preparedness ↗
- Oct 25, 2026 TrialsLibtayo® (cemiplimab) Longer-Term Data Show Increasing and Clinically Meaningful Overall Survival Benefit with Adjuvant Treatment in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) ↗
Regeneron's Recent FDA Approvals
Regeneron secured 2 new FDA approvals for novel drugs (NDA/BLA) in the last two years.
Regeneron's Therapeutic Areas
Regeneron's approved drugs and pipeline span 5 therapeutic areas, led by Oncology and Cardiovascular, across 10 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
Regeneron's Top Competitors
Regeneron's closest competitors by therapeutic-area and drug-target overlap include Baxter, Bayer, and B BRAUN. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
Regeneron Pipeline Snapshot
Regeneron has 171 active clinical programs from ClinicalTrials.gov — 49 Phase 3, 60 Phase 2 and 62 Phase 1.
Phase 3 Readout Calendar Pro
8 Phase 3 trials with confidence-graded primary completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Pro Intelligence Preview
Deep insights for investors and analysts
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 43/85 completed
- • Speed: 19 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges